Teva's no-risk look at oral tolerance

AutoImmune Inc. announced that Teva Pharmaceutical Industries Ltd. has obtained the right to apply AIMM's oral tolerance technology to develop TEVIY's Copaxone glatiramer for multiple sclerosis as an oral immune modulator. But while TEVIY walked away with intellectual property rights, AIMM gets nothing unless a TEVIY product incorporating AIMM's technology reaches the market.

TEVIY also licensed the right to apply oral tolerance technology to a compound to treat myasthenia gravis. TEVIY will pay AIMM up to $20 million in milestones triggered by product approvals in major markets. TEVIY is conducting all formulation development and trials, and AIMM is eligible for royalties...